Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (buparlisib)

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3458-3471

  Matas Céspedes, Alba ^a   Rodriguez, Vanina ^a   Kalko, Susana G ^b   Vidal Crespo, Anna ^a   Rosich, Laia ^a   Casserras, Teresa ^b   Balsas, Patricia ^a   Villamor, Neus ^c   Giné, Eva ^d   Campo, Elías ^c   Roué, Gaël ^a   López Guillermo, Armando ^d   Colomer, Dolors ^a,c   Pérez Galán, Patricia ^a,d  

^a Experimental Therapeutics in Lymphoid Malignancies Group Department of Hemato Oncology   (Spain)

^b Bioinformatics Core Facility   (Spain)

^c Hematopathology Unit Department of Pathology   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; CHEMOKINE RECEPTOR CXCR4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTOME; AMINOPYRIDINE DERIVATIVE; MORPHOLINE DERIVATIVE; NVP-BKM120;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL ADHESION ASSAY; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION ASSAY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL COMMUNICATION; CELL MOTION; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EXTRACELLULAR MATRIX; GENETICS; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

AMINOPYRIDINES; ANIMALS; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINE CXCL12; CLUSTER ANALYSIS; DENDRITIC CELLS, FOLLICULAR; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, FOLLICULAR; MICE; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903831904     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0154     Document Type: Article

References (50)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403: 503-11.
2. Lossos IS, Levy R. Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003;13: 191-202.
3. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108: 2957-64.
4. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27: 1470-6.
5. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159-69.
6. Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105: 301-7.
7. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25: 390-8.
8. Harjunpaa A, Taskinen M, Nykter M, Karjalainen-Lindsberg ML, Nyman H, Monni O, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006;135: 33-42.
9. Ribatti D, Nico B, Ranieri G, Specchia G, Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013;15: 231-8.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9: 669-76.
11. De RH, Van ME, Van CB, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 2004;19: 935-50.
12. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106: 511-21.
13. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013;328: 18-26.
14. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009;50: 1647-60.
15. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010;95: 2157-60.
16. Taskinen M, Jantunen E, Kosma VM, Bono P, Karjalainen-Lindsberg ML, Leppa S. Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. Eur J Cancer 2010;46: 2506-12.
17. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000;95: 1900-10.
18. Pals ST, Drillenburg P, Radaszkiewicz T, Manten-Horst E. Adhesion molecules in the dissemination of non-Hodgkin's lymphomas. Acta Haematol 1997;97: 73-80.
19. Terol MJ, Lopez-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, et al. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999;17: 1869-75.
20. Cunningham SA, Waxham MN, Arrate PM, Brock TA. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 1995;270: 20254-7.
21. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-43.
22. Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood 2008;112: 3818-26.
23. Gulmann C, Espina V, Petricoin E III, Longo DL, Santi M, Knutsen T, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005;11: 5847-55.
24. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E III, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004;84: 235-44.
25. Kim HS, Zhang X, Choi YS. Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. J Immunol 1994;153: 2951-61.
26. Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004;573: 83-92.
27. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006;210: 67-85.
28. Kleinman HK, Cid MC. Preparation of endothelial cells. Curr Protoc Cell Biol 2001;Chapter 2: Unit 2.3.
29. Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, et al. ON 01910. Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012; 18: 1979-91.
30. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102: 19-65.
31. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011;63: 610-5.
32. Chen HC, Guan JL. Stimulation of phosphatidylinositol 3′-kinase association with foca adhesion kinase by platelet-derived growth factor. J Biol Chem 1994;269: 31229-33.
33. Reiske HR, Kao SC, Cary LA, Guan JL, Lai JF, Chen HC. Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem 1999;274: 12361-6.
34. Lee CG, Das B, Lin TL, Grimes C, Zhang X, Lavezzi T, et al. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interactswith follicular dendritic cells to maintain tumourigenic potential. Br J Haematol 2012;158: 79-90.
35. Corcione A, Ottonello L, Tortolina G, Facchetti P, Airoldi I, Guglielmino R, et al. Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst 2000;92: 628-35.
36. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, et al. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113: 5549-57.
37. Haribabu B, Richardson RM, Fisher I, Sozzani S, Peiper SC, Horuk R, et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 1997;272: 28726-31.
38. Kagami Y, Jung J, Choi YS, Osumi K, Nakamura S, Morishima Y, et al. Establishment of a follicular lymphoma cell line (FLK-1) dependent on follicular dendritic cell-like cell line HK. Leukemia 2001;15: 148-56.
39. Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in SCID mice. BMC Cancer 2005;5: 103.
40. Allen CD, Cyster JG. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 2008;20: 14-25.
41. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995;147: 912-22.
42. Choe J, Li L, Zhang X, Gregory CD, Choi YS. Distinct role of follicular dendritic cells and T cells in the proliferation, differentiation, and apoptosis of a centroblast cell line, L3055. J Immunol 2000;164: 56-63.
43. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010;24: 1781-4.
44. Fruchon S, Kheirallah S, Al ST, Ysebaert L, Laurent C, Leseux L, et al. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012;26: 795-805.
45. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11: 317-28.
46. Rosich L, Saborit-Villarroya I, Lopez-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M, et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013;98: 1739-47.
47. Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, et al. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVPBKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55: 425-34.
48. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 2012;90: 695-706.
49. Bendell JC, Rodon J, Burris HA, de JM, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30: 282-90.
50. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285: 1182-6.